Rationale and design of the Renal Lifecycle trial assessing the effect of dapagliflozin on cardiorenal outcomes in severe chronic kidney disease.

Explores the emerging role of SGLT2 inhibitors in preserving residual renal function and improving cardiovascular health in peritoneal dialysis patients.